Donate

Webinar: Life After Lymphoma Treatment: Early Effects and Long-Term Survivorship

Lymphoma Australia invites you to our next free educational webinar tailored to patients, families, and carers of those affected Lymphoma.

This session will explore life after treatment for lymphoma, involving navigating a new normal, managing long-term side effects, and coping with the impacts of finishing treatment.

Guest Presenter

Dr Angeline Josiah

BSc MPhil MChD FRACP FRCPA
Post Graduate Fellow in Lymphoma
 
Dr Angeline Josiah began her career as a molecular biologist, completing a Master of Philosophy Degree in Biochemistry and Molecular Biology from the Australian National University. She worked in public health policy before embarking on her medical degree, graduating as Doctor of Medicine & Surgery (MChD) in 2015.
 
 
She completed her medical training at Canberra Hospital followed by dual specialist training in Haematology both in Canberra and in NSW at Westmead, Blacktown & Nepean Hospitals. On attaining fellowships from both the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia she commenced work as Concord’s Post Graduate Fellow in Lymphoma.
 
 
Dr Josiah is an emerging lymphoma leader committed to excellence in patient care & research, fostering multidisciplinary partnerships and mentoring junior doctors. Dr Josiah is an investigator on the MyHodgkin MyHealth project: a digital survivorship platform capturing patient derived data. Her research includes integrating patient-reported outcome measures on quality of life, financial toxicity & education into the MHMH app to enable long-term, real-world data collection that meaningfully informs survivorship care.
 

For more info email nurse@lymphoma.org.au or call the Nurse Support Line on 1800 953 081.

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Monday 23rd of February 2026
Time: 4:00pm AEDT - 5:00pm AEDT

For more info email: nurse@lymphoma.org.au or phone 1800 953 081.
Register to attend
Watch recording
Download Flyer

Support and information

Support Groups & Social Media

Find Out More

Factsheets & Booklets

Find Out More

Fundraise for us

Get started

Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.